Compounded Peptides ·
503A compounding pharmacies prepare customized preparations for specific patients based on individual prescriptions. They are regulated primarily at the state level by boards of pharmacy, although FDA retains certain authorities. 503B outsourcing facilities, by contrast, voluntarily register with FDA and operate under cGMP-equivalent requirements; they can prepare batches of sterile drug products for sale to hospitals and clinics without a patient-specific prescription. For compounded GLP-1 drugs, the distinction matters because 503A pharmacies must justify 'clinical difference' for each patient, while 503B facilities must source active ingredients from FDA-registered bulk substance suppliers. Many of the Eli Lilly lawsuits filed through 2025 and 2026 argue that certain telehealth-affiliated compounders operated outside both lanes.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.